News und Analysen
Agilent BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology
Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the
Agilent Reports Fourth-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.69 billion for the fourth quarter ended Oct. 31, 2023, a decline of 8.7% reported and 9.7% core(1) compared to the fourth quarter of
Agilent to Present at the Evercore ISI HealthCONx Conference
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI
Agilent Increases Cash Dividend to 23.6 Cents per Share
Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend. The quarterly
Value-Based Care Benefits Patients and Physicians, New Report Shows
Value-based care is smarter healthcare that lowers costs and keeps Medicare Advantage members healthier, according to the tenth annual Value-Based Care Report released today from Humana Inc. (NYSE
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or
Agilent Announces Thought Leader Award to Professor Jennifer Field
Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader
Humana Healthy Horizons partners with the Alzheimer’s Association to educate and support Floridians
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), is forging a path to better outcomes for those impacted by Alzheimer’s Disease and
Humana Announces Four New Sponsorships of Leading U.S. Pickleball Organizations to Inspire and Promote Active and Healthy Lifestyles for All Ages, With a Special Focus on Seniors
In recognition of pickleball’s rapidly growing popularity in the U.S., the increasing need for court space across the country, and the sport’s life-changing benefits both on and off the courts
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
Pfizer Inc. (NYSE: PFE) will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH)
Pfizer Reports Third-Quarter 2023 Results
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance(4) range of $58.0 to $61.0 billion and its outlook for Adjusted(3)
Humana and Greater Good Health Expand Access to Primary Care in Montana with Opening of Senior-focused Primary Care Clinics
Humana, a leading health and well-being company, and Greater Good Health, a healthcare organization expanding access to primary care for seniors through a nurse practitioner-led value-based care
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of
Agilent to Announce Fourth-Quarter Fiscal Year 2023 Financial Results Nov. 20
Agilent Technologies Inc. (NYSE: A) will release financial results for the fourth quarter of fiscal year 2023 after the stock market closes on Monday, Nov. 20. In addition, the company will host a
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent
Agilent’s Net-Zero Emissions Targets Approved by the Science Based Targets Initiative
Agilent Technologies Inc. (NYSE: A) today announced the company’s near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the Science Based Targets
Humana’s Medicare Advantage Footprint in New Jersey Complete
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its health plans to Middlesex County, widening the company’s Medicare Advantage footprint to 100% of the state.
For the
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the
Humana and Denver Health Sign Agreement to Expand Humana’s Medicare Advantage Provider Network in the Denver Area
Humana, a leading health and well-being company, and Denver Health, a comprehensive health and hospital system, have entered into an agreement that broadens access to care for Humana Medicare